Results 191 to 200 of about 68,398 (251)

A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial. [PDF]

BMC Cancer, 2021
Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, Möller P, Barth TFE, Muche R, Dreyhaupt J, Raderer M, Kiesewetter B, Buske C.   +11 more
europepmc   +1 more source

Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma. [PDF]

J Vet Intern Med
McLinden GP, Avery AC, Gardner HL, Hughes K, Rodday AM, Liang K, London CA.   +6 more
europepmc   +1 more source

Anti-CD20/CD3 Monoclonal Antibody XmAb13676 [PDF]

, 2020
openaire   +1 more source

Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy. [PDF]

Eur J Clin Microbiol Infect Dis
Feuth E, Nieminen V, Palomäki A, Ranti J, Sucksdorff M, Finnilä T, Oksi J, Vuorinen T, Feuth T.   +8 more
europepmc   +1 more source

Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study. [PDF]

Lancet Reg Health West Pac
Xu M, Shu J, Qian S, Guo J, Gong Y, Huang R, Wang S, Zhou Z, Yuan G, Huang M, Lin LE, Lou S, Song Y, Liu Q, Zhou H, Mei H, Hu Y.   +16 more
europepmc   +1 more source

[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Qin SC, Miao Y, Zhang ZL, Zhang J, Shi YY, Miao YQ, Gu WY, Zheng WC, Jia ZX, Lin GQ, Ni HW, Xu XH, Xu M, Xie XY, Wang L, Zhuang Y, Zhang W, Liu P, Li JY, Shi WY.   +19 more
europepmc   +1 more source

Anti-CD20/CD3 Monoclonal Antibody REGN1979 [PDF]

, 2020
openaire   +1 more source

Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial. [PDF]

EClinicalMedicine
Shi Y, Zhou K, Zhou H, Qin Y, Jing H, Xiang Y, Wang Z, Wang Z, Zang A, Bai O, Li Z, Zhang H, Song Y, Liang J, Wei M.   +14 more
europepmc   +1 more source